Search
Member Login

Public Health Emergency to End May 11

The federal Public Health Emergency (PHE) is scheduled to end of May 11, 2023, which will create changes to how healthcare has been delivered these past three years. Under the PHE, a number of restrictions were lifted to help patients receive services; many of the pre-pandemic rules will go back into place when the PHE ends. For example, health care professionals will be required to use a HIPAA-complaint software for telehealth.

NEW! The DEA is considering changes to the ability to prescribed controlled substances via telemedicine. The telehealth flexibilities will remain intact until at least November 11, 2023.

The DEA's proposed rule for prescriptions of telemedicine include controlled substances and medication for opioid use disorder. The following is a summary of the proposed rules:

Relationship between prescribing medical practitioner and patient


 Prescribing a non-controlled medication Prescribing Schedule III, IV, or V non-narcotic
controlled medications		 Prescribing buprenorphine as medication for opioid use disorder Prescribing Schedule II and/or narcotic controlled medications
Prior in-person medical evaluation by prescribing medical practitioner Permitted Permitted Permitted Permitted
Referral under the proposed rules from medical practitioner who conducted prior in-person medical evaluation Permitted Permitted Permitted Permitted

Telehealth visit without:

  • Prior in-person medical evaluation by prescribing medical practitioner; or
  • Referral from a medical practitioner who conducted prior in-person medical evaluation
 Permitted
  • Up to 30-day initial prescription
  • In-person visit required for additional prescription
  • Up to 30-day initial prescription
  • In-person visit required for additional prescription
 Not permitted

 

Under these proposed rules, a practitioner may prescribe a controlled substance only after a telemedicine visit if the prescription is a non-narcotic Schedule III, IV, or V controlled substance (or buprenorphine), and the prescription is limited to a 30-day supply. For these prescriptions listed above, the patient must have an in-person appointment before they can continue their treatment past 30-days. 

The in-person medical evaluation can be completed by: the prescribing provider or by another DEA registered provider that results in a "qualified telemedicine referral." The referral must include the diagnosis, evaluation, or treatment that was provided to the patient. The referring provider and prescribing provider must document the referral in the medical record.

After the in-person visit, the prescribing practitioner can continue to prescribe the controlled medication without additional in-person appointments. 

For patients who established care during the PHE (between 1/30/2020 and 11/11/2023), the patient will have up to a year (11/11/2024) to have an in-person appointment.

There will be increased record keeping requirements under the proposed rule, the prescribing provider must notate on the prescription/order that the prescription is being issued via telemedicine. The prescriber must also use all efforts to access the Prescription Drug Monitoring Program, or PDMP, (in NC, this is the Controlled Substance Reporting System) to review the patients prescription history for the past year. If the prescriber cannot access the PDMP, only a 7-day supply of the medication can be prescribed. 

Other changes when the PHE ends will include:

  • Those with private insurance will no longer receive eight free at-home COVID tests each month, but those on Medicaid will be able to access COVID tests until 2024 under the American Rescue Plan.
  • In NC, an estimated 300,000 people will lose eligibility for health care coverage under Medicaid.
  • Those with private insurance will now pay a co-pay for treatments like Paxlovid as well as PCR tests.

Many states and insurers have made permanent changes to telehealth, which are no longer linked to the PHE. The Consolidated Appropriations Act of 2023 extended telehealth flexibilities for Medicare patients, including postponing in-person requirements until at least the end of 2024.

For psychiatrists who transitioned from an office-based to a hybrid or fully virtual role, the APA has created several resources to help make sense of the expected changes to come:

  • “Best Practices in Synchronous Videoconferencing-Based Telemental Health”: This document provides guidance on addressing the key administrative, technical, and clinical considerations when using a telehealth platform. The document—which covers such topics as legal and regulatory issues as well as telehealth platforms—was created by a joint writing committee drawn from the APA Committee on Telepsychiatry and the American Telemedicine Association Telemental Health Special Interest Group.

  • “What Happens When the Public Health Emergency Ends? Telepsychiatry and Hybrid Practice Post-PHE”: This webinar—featuring a 60-minute presentation exploring some of the regulations to change when the PHE lifts, followed by a Q&A—was recorded on January 11. It was hosted by Shabana Khan, M.D., the director of the child and adolescent telepsychiatry program at NYU Langone Health, and John Torous, M.D., director of digital psychiatry at Beth Israel Deaconess Medical Center. Khan is the chair of APA’s Committee on Telepsychiatry, and Torous is the chair of APA’s Committee on Mental Health Information Technology.

  • “Comparison of Telehealth Provisions During & After the Public Health Emergency”: This table summarizes the topics discussed in the webinar mentioned above and provides a quick reference on the telehealth provisions enacted during the PHE, their likely status post-emergency, and anticipated kick-in date.

 Resources

  1. DEA Proposed Rules for Permanent Telemedicine Flexibilities (Feb. 24, 2023)
  2. DEA's Proposed Telemedicine Regulations, Highlights for Medical Practitioners
  3. Manatt DEA Releases Proposed Rules Regarding Telemedicine Prescribing of Controlled Substances